講  題：Resistance in oncolytic viral therapy for malignant tumors

講  師：Sophia Jang 教授 (Texas Tech University)

時  間： 2024年 7月 25 日 (星期三)  13:10-14:00

地  點：靜安樓325室

 摘 要

    Therapeutic resistance poses a significant obstacle in cancer control, and oncolytic viral therapy also faces the challenge of virus resistance. In this talk, we introduce models based on ordinary and delay differential equations to investigate the impact of resistance on tumor-virus interactions. The tumor cells are categorized as sensitive, resistant, or infected by oncolytic viruses. We show that if resistant tumor cells cannot be transformed into sensitive cells, every tumor cell will eventually acquire resistance. The model can possess at most one positive equilibrium, and we determine the critical delay magnitude beyond which the equilibrium becomes unstable. Our numerical simulations indicate that delays in the viral cycle can result in an increase in the total tumor burden. However, in terms of the overall tumor load, resistance may not be detrimental to the host if the delay in the viral cycle is substantial.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

講  題：The role of immune cells in resistance to oncolytic viral Therapy

講  師：Sophia Jang 教授 (Texas Tech University)

時  間： 2024年 7月 25 日 (星期三)  14:10-15:00

地  點：靜安樓325室

 摘 要

   In the second talk, we incorporate immune cells into the models to explore the effect of resistance on oncolytic viral therapy. Immune cells can eliminate both tumor cells and viruses. Our research shows that the introduction of immune cells into the tumor-virus interaction prevents all tumor cells from becoming resistant in the absence of conversion from resistance to sensitivity, given that the proliferation rate of immune cells exceeds their death rate. The inclusion of immune cells leads to an additional virus-free equilibrium when the immune cell recruitment rate is sufficiently high. The total tumor burden at this virus-free equilibrium is smaller than that at the virus-free and immune-free equilibrium. Therefore, immune cells are capable of reducing the tumor load under the condition of sufficient immune strength. Numerical investigations reveal that the virus transmission rate and parameters related to the immune response significantly impact treatment outcomes. However, monotherapy alone is insufficient for eradicating tumor cells, necessitating the implementation of additional therapies.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

聯絡人：余瑞琳教授 jlyu@gm.pu.edu.tw

連絡電話：04-26328001轉15115